STAT3 and IL-17-Th17 in skin immunity to MRSA
STAT3 和 IL-17-Th17 在皮肤对 MRSA 的免疫中的作用
基本信息
- 批准号:8903440
- 负责人:
- 金额:$ 35.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-09 至 2015-09-08
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdmission activityAntibiotic ResistanceBacteriaCD4 Positive T LymphocytesCD8B1 geneCandidaCandida albicansCellsChemotaxisChronicCommunitiesCutaneousDevelopmentEczemaEmbryoEpidemicFurunclesFutureGenerationsHospitalsHost DefenseHost Defense MechanismHumanImmuneImmune TargetingImmune responseImmunityImpairmentInfectionInfectious Skin DiseasesInflammatoryInterleukin-17Job&aposs SyndromeLightMeasuresMonitorMusMutationMyeloid CellsNecrosisNeutrophil InfiltrationOccupationsOutpatientsPathogenesisPatientsPhenotypePlayProductionPsoriasisPublic HealthRare DiseasesRecurrenceRisk FactorsRoleSCID MiceSignaling MoleculeSkinSkin TissueSoft Tissue InfectionsStaphylococcus aureusStat3 proteinT-LymphocyteT-Lymphocyte SubsetsTechnologyTestingTherapeuticTimeVaccinationVirulentVisitXenograft Modelantimicrobialantimicrobial peptidebasecombatcytokineextracellularin vivoin vivo Modelinnovationkeratinocyteloss of function mutationmethicillin resistant Staphylococcus aureusmouse modelneutralizing antibodyneutrophilnoveloptical imagingpathogenreconstitutionresearch studyresistant strainresponseskin disordertranscription factor
项目摘要
Staphylococcus aureus is the most common cause of skin and soft tissue infections (SSTIs) in humans, which
result in 14 million outpatient visits and half of a million hospital admissions per year in the U.S. Moreover, the
epidemic of community-acquired methicillin-resistant S. aureus (CA-MRSA) in the past 2 decades has become
an enormous public health threat, as virulent and antibiotic resistant strains are causing severe and necrotic
SSTIs in healthy people outside hospital settings (and without risk factors for infection). The experiments in this
proposal will build on the observations in humans with the rare orphan disease Hyper-IgE syndrome, who
suffer from an eczema-like skin eruption and chronic and recurrent skin infections with S. aureus. These
patients were found to have loss-of-function mutations in the signaling molecule STAT3 and a deficiency in
Th17 cells, suggesting that STAT3 and IL-17/Th17 responses are essential for cutaneous host defense against
S. aureus. Although IL-17/Th17 responses in skin have been implicated in the chronic inflammatory skin
disease psoriasis, little is known about the host defense role of IL-17/Th17 responses during an acute MRSA
skin infection. The overall hypothesis of this proposal is that STAT3 and IL-17/Th17 protective cutaneous
immune responses against MRSA in skin are induced by cytokine cross-talk between keratinocytes and T
cells. This study has three aims. Aim 1 will evaluate the host defense role of STAT3 in keratinocytes. Aim 2 will
evaluate the differential role of STAT3 in T cell subsets during primary infection and reinfection of MRSA in
skin. Aim 3 will determine the mechanisms of STAT3 in human keratinocytes to promote host defense
mechanisms, including antimicrobial peptide production and neutrophil responses. To test these hypotheses,
we have developed an innovative mouse model S. aureus/MRSA skin infection that combines light-emitting
bacteria with in vivo optical imaging to noninvasively monitor the bacterial burden in the infected skin by
measuring the amount of emitted light in anesthetized mice over time. In addition, a human skin/SCID mouse
xenograft model, human organotypic keratinocyte cultures and keratinocytes from Hyper-IgE syndrome
patients. This study will provide a broad and sustained impact to the field by defining the key cutaneous host
defense mechanisms against S. aureus/MRSA, an important human bacterial skin pathogen. The proposed
experiments will define the cytokine interactions induced by STAT3 between keratinocytes and T cells to
promote host defense against MRSA in the skin. Finally, this study may uncover novel cutaneous immune
mechanisms that could be targeted in the future development of immune-based therapeutic strategies to help
combat S. aureus/MRSA infections in humans.
金黄色葡萄球菌是人类皮肤和软组织感染(SSTI)的最常见原因,
导致1400万个门诊就诊,每年在美国接受住院的一半,此外,
在过去的20年中
巨大的公共卫生威胁,因为有毒和抗生素抗性菌株正在引起严重和坏死
医院环境外健康人员的SSTI(没有感染的危险因素)。其中的实验
提案将建立在人类的观察结果的基础上
患有湿疹样的皮肤喷发,以及金黄色葡萄球菌的慢性和复发性皮肤感染。这些
发现患者在信号分子STAT3中具有功能丧失突变,并且缺乏
Th17细胞,表明STAT3和IL-17/TH17反应对于皮肤宿主防御至关重要
S.金黄色葡萄酒。尽管皮肤中的IL-17/TH17反应已与慢性炎症性皮肤有关
疾病牛皮癣,对急性MRSA期间IL-17/TH17反应的宿主防御作用知之甚少
皮肤感染。该提议的总体假设是STAT3和IL-17/TH17保护性皮肤
角质形成细胞和T之间的细胞因子串扰诱导了针对皮肤中MRSA的免疫反应
细胞。这项研究有三个目标。 AIM 1将评估STAT3在角质形成细胞中的宿主防御作用。 AIM 2意志
评估STAT3在原发性感染过程中STAT3在T细胞亚群中的差异作用,并在MRSA中重新感染
皮肤。 AIM 3将确定人角质形成细胞中Stat3的机制促进宿主防御
机制,包括抗菌肽的产生和中性粒细胞反应。为了检验这些假设,
我们已经开发了一种创新的小鼠模型S.金黄色素器/MRSA皮肤感染,结合了发光
带有体内光学成像的细菌,可无创地监测受感染皮肤的细菌负担
随着时间的推移,测量麻醉小鼠中发出的光量。另外,人类的皮肤/SCID鼠标
异种移植模型,Hyper-Ige综合征的人体器官角质形成细胞培养物和角质形成细胞
患者。这项研究将通过定义关键皮肤宿主对现场产生广泛而持续的影响
针对金黄色葡萄球菌/MRSA的防御机制,这是一种重要的人类细菌皮肤病原体。提议
实验将定义角质形成细胞和T细胞之间STAT3引起的细胞因子相互作用
促进对皮肤中MRSA的宿主防御。最后,这项研究可能会发现新颖的皮肤免疫
可能针对未来基于免疫的治疗策略的机制来帮助
战斗S.金黄色葡萄球菌/MRSA感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lloyd S Miller其他文献
Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model
从化脓性汗腺炎异种移植小鼠模型的开发中吸取的经验教训
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Q. Q. Quartey;Robert J. Miller;B. Pinsker;U. J. Okoh;William D Shipman;Beth A George;Chibuikem Nwizu;L. Barnes;M. Kerns;J. Caffrey;O. Aliu;Isabelle D. Brown;Farah Succaria;J. Maynard;Amber S Herbert;Sewon Kang;Lloyd S Miller;G. Okoye;A. Byrd - 通讯作者:
A. Byrd
Lloyd S Miller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lloyd S Miller', 18)}}的其他基金
Human in vivo Th17 cell responses in cutaneous immunity to Staphylococcus aureus
人体内 Th17 细胞对金黄色葡萄球菌皮肤免疫的反应
- 批准号:
9196957 - 财政年份:2016
- 资助金额:
$ 35.64万 - 项目类别:
STAT3-mediated immunity to Staphylococcus aureus in skin
STAT3介导的皮肤金黄色葡萄球菌免疫
- 批准号:
9055474 - 财政年份:2016
- 资助金额:
$ 35.64万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
8012861 - 财政年份:2009
- 资助金额:
$ 35.64万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
7590055 - 财政年份:2009
- 资助金额:
$ 35.64万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
8417741 - 财政年份:2009
- 资助金额:
$ 35.64万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
8213386 - 财政年份:2009
- 资助金额:
$ 35.64万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
7761267 - 财政年份:2009
- 资助金额:
$ 35.64万 - 项目类别:
Host defense against Staphylococcus aureus skin infections
宿主防御金黄色葡萄球菌皮肤感染
- 批准号:
7513375 - 财政年份:2008
- 资助金额:
$ 35.64万 - 项目类别:
Host defense against Staphylococcus aureus skin infections
宿主防御金黄色葡萄球菌皮肤感染
- 批准号:
7651292 - 财政年份:2008
- 资助金额:
$ 35.64万 - 项目类别:
Host defense against Staphylococcus aureus skin infections
宿主防御金黄色葡萄球菌皮肤感染
- 批准号:
7799065 - 财政年份:2008
- 资助金额:
$ 35.64万 - 项目类别:
相似海外基金
Predicting the Absence of Serious Bacterial Infection in the PICU
预测 PICU 中不存在严重细菌感染
- 批准号:
10806039 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Prognostic modeling of pediatric tracheostomy-associated respiratory tract infections
儿童气管切开相关呼吸道感染的预后模型
- 批准号:
10661889 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Targeted Contact Precaution Use to Prevent MRSA Transmission
使用有针对性的接触预防措施来防止 MRSA 传播
- 批准号:
10178338 - 财政年份:2021
- 资助金额:
$ 35.64万 - 项目类别:
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
纽约大学疫苗和治疗评估中心(NYU VTEU)成立
- 批准号:
10493613 - 财政年份:2021
- 资助金额:
$ 35.64万 - 项目类别: